Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15015625rdf:typepubmed:Citationlld:pubmed
pubmed-article:15015625lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15015625lifeskim:mentionsumls-concept:C1825590lld:lifeskim
pubmed-article:15015625lifeskim:mentionsumls-concept:C2697648lld:lifeskim
pubmed-article:15015625lifeskim:mentionsumls-concept:C0332174lld:lifeskim
pubmed-article:15015625lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:15015625lifeskim:mentionsumls-concept:C0023413lld:lifeskim
pubmed-article:15015625lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:15015625lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:15015625lifeskim:mentionsumls-concept:C0069717lld:lifeskim
pubmed-article:15015625lifeskim:mentionsumls-concept:C1285530lld:lifeskim
pubmed-article:15015625pubmed:issue1lld:pubmed
pubmed-article:15015625pubmed:dateCreated2004-3-12lld:pubmed
pubmed-article:15015625pubmed:abstractTextThe aim of this work was to evaluate the efficacy and safety of second-line treatment with weekly high-dose 5-Fluorouracil (5-FU) as a 24-hour infusion (24-h inf.) and folinic acid (FA) (AIO-regimen) plus Oxaliplatin (L-OHP) after pre-treatment with the AIO regimen, focusing in particular on the efficacy of palliative first- and second-line treatment in colorectal carcinoma (CRC).lld:pubmed
pubmed-article:15015625pubmed:languageenglld:pubmed
pubmed-article:15015625pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015625pubmed:citationSubsetIMlld:pubmed
pubmed-article:15015625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015625pubmed:statusMEDLINElld:pubmed
pubmed-article:15015625pubmed:issn0250-7005lld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:LinnLLlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:WeilCClld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:MerkelSSlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:HahnE GEGlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:HohenbergerWWlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:GöhlJJlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:BrücklW MWMlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:HappichKKlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:SchirnerIIlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:JüngertBBlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:BrücklVVlld:pubmed
pubmed-article:15015625pubmed:authorpubmed-author:MännleinGGlld:pubmed
pubmed-article:15015625pubmed:issnTypePrintlld:pubmed
pubmed-article:15015625pubmed:volume24lld:pubmed
pubmed-article:15015625pubmed:ownerNLMlld:pubmed
pubmed-article:15015625pubmed:authorsCompleteYlld:pubmed
pubmed-article:15015625pubmed:pagination385-91lld:pubmed
pubmed-article:15015625pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:meshHeadingpubmed-meshheading:15015625...lld:pubmed
pubmed-article:15015625pubmed:articleTitlePalliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).lld:pubmed
pubmed-article:15015625pubmed:affiliationDepartment of Internal Medicine I, University of Erlangen, Germany.lld:pubmed
pubmed-article:15015625pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15015625pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15015625pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15015625pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed